Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 3/20 | 0.64 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | GIPR | P48546 | 1/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.60 |
| ▸ | TLR2 | O60603 | 4/20 | 0.58 |
| ▸ | PTH1R | Q03431 | 4/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29608081 | 0.98 | GLP1R (0.62) | GLP1RGCGRGIPRIL23RTLR2 | |
| SCHEMBL29549608 | 0.91 | KISS1R (0.57) | GLP1RGCGRGIPRIL23RTLR2 | |
| SCHEMBL29525144 | 0.91 | GLP1R (0.68) | GLP1RGCGRGIPRIL23RPTH1R | |
| SCHEMBL29695585 | 0.90 | GLP1R (0.62) | GLP1RGCGRGIPRIL23RTLR2 | |
| SCHEMBL29664866 | 0.90 | GLP1R (0.59) | GLP1RGCGRGIPRTLR2KISS1R | |
| SCHEMBL30376709 | 0.90 | GLP1R (0.57) | GLP1RGCGRGIPRKISS1R | |
| SCHEMBL29525856 | 0.90 | IL23R (0.58) | GLP1RGCGRGIPRIL23RTLR2 | |
| SCHEMBL30262119 | 0.89 | GLP1R (0.62) | GLP1RGCGRGIPRIL23RPTH1R | |
| SCHEMBL31182787 | 0.89 | GLP1R (0.65) | GLP1RGCGRGIPRIL23RTLR2 | |
| SCHEMBL29607306 | 0.89 | TLR2 (0.59) | GLP1RGCGRGIPRIL23RTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | GLP1R 1/4885GCGR 3/4885GIPR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.